Cinryze(™) as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety

Hereditary angioedema (HAE) is a clinical disorder characterized by a deficiency of C1 esterase inhibitor (C1-INH). HAE has traditionally been divided into two subtypes. Unique among the inherited deficiencies of the complement system, HAE Types I and II are inherited as an autosomal dominant disord...

Descripción completa

Detalles Bibliográficos
Autores principales: Lunn, Michael, Santos, Carah, Craig, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262319/
https://www.ncbi.nlm.nih.gov/pubmed/22282695
http://dx.doi.org/10.2147/JBM.S9576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262319/
https://www.ncbi.nlm.nih.gov/pubmed/22282695
http://dx.doi.org/10.2147/JBM.S9576

Ejemplares similares